Role of LFA-1/ICAM-1, CLA/E-selectin and VLA-4/VCAM-1 Pathways in Recruiting Leukocytes to the Various Regions of the Chronic Leg Ulcer

KARLI ROSNER1,2, CHRISTIAN ROSS3, TONNY KARLSMARK4 and GUNHILD LANGE SKOVGAARD1,2

1Laboratory for Molecular Gerontology and Dermatology, Rigshospitalet, University Hospital of Copenhagen, 2Department of Dermatology, Bispebjerg Hospital, Copenhagen, 3Institute for Inflammatory Research, Rigshospitalet, University Hospital of Copenhagen, and 4Sore Center, Bispebjerg Hospital, Copenhagen, Denmark

The center, edge and distant regions of the venous leg ulcer differ in inflammatory cell composition, suggesting that these represent different developmental stages. Our goal was to determine which recruitment pathways contribute to the differences in leukocyte composition between the various ulcer regions. The multiple region biopsy approach, which enables to study the different development phases of the ulcer at one time-point, was employed to immunohistochemically identify the vascular adhesion molecules E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), and their counter-ligands on extravasated leukocyte cutaneous lymphocyte-associated antigen (CLA), lymphocyte function-associated antigen (LFA-1) and very late activation antigen-4 (VLA-4), respectively. E-selectin expression was highest at the ulcer edge, while ICAM-1 was highest at the ulcer center. VCAM-1 expression was minor at all ulcer regions. CLA stained up to 80% of the epidermal Langerhans’ cells, 62% of the T cells, and only 9% of the macrophages. LFA-1 did not stain Langerhans’ cells, stained up to 89% of the T cells and up to 11% of the macrophages. VLA-4 stained up to 30% of the T cells and 71% of the macrophages. In conclusion, the results indicate that Langerhans’ cells, T cells and macrophage are each recruited by more than one adhesion-molecule pathway to any of the chronic venous leg ulcer regions. Key words: adhesion molecule; cutaneous lymphocyte-associated antigen; venous leg ulcer; wound healing.

(Accepted July 30, 2001.)

Acta Derm Venereol 2001; 81: 334–339.

Karli Rosner, Laboratory of Molecular Gerontology and Dermatology, Rigshospitalet, Section 6311, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark. E-mail: rosner@mail.dk

METHODS

Patients

Nineteen patients (12 men and 7 women; mean age 71 years (range 41–93)) were included in the study after giving written consent (15). Mean duration of the ulcer was 34.1 months (range 3–180) and mean ulcer area was 24 cm² (range 1–200). Three patients received topical steroids. None received systemic immunosuppressive therapy. The study was approved by the local ethics committee of Copenhagen, Denmark.

Specimens

Three-millimeter punch biopsies were obtained from the center, the edge and from macroscopically intact skin 2 cm from the edge of the ulcer (15). The “center” was defined as area devoid of epidermis located 2 cm apart from the area covered by epidermis when the
shorter diameter of this area was more than 4 cm. Otherwise, the center was the middle of the area if the longest diameter was 4 cm or less. The “edge” was defined as tissue containing epidermis and dermis immediately adjacent to an area devoid of epidermis. The biopsies were snap-frozen and stored at −80°C. Serial 3-mm thick sections were cut, air-dried overnight at room temperature, fixed in acetone for 10 min and stored at −80°C until further processed. The stainings were conducted on the same biopsies that previously served to identify the inflammatory cell composition at the various ulcer regions (15).

Antibodies

The primary monoclonal antibodies are listed in Table I. All the secondary and tertiary antibodies were purchased from DAKO, Glostrup, Denmark.

Single-staining procedure

A three-step immunoperoxidase method was performed as previously described (16). In brief, the specimens were incubated sequentially with unlabelled primary monoclonal antibody, peroxidase-conjugated rabbit anti-mouse IgG (DAKO, Glostrup, Denmark) and swine antirabbit IgG (DAKO). Each incubation step was 30 min with 5-min TRIS-buffered saline (TBS) washes between. Peroxidase activity was visualized by incubating the specimens with 3-amino-9-ethyl-carbazole (AEC) (Sigma, St. Louis, MO, USA) for 10 min, giving an orange color. The specimens were then counterstained with hematoxylin and mounted in glycerol (DAKO). Single-staining for E-selectin was performed on endothelial cells.

Double-staining procedure

Double-staining was performed sequentially by three-step immunoperoxidase (16) and immunooalkaline phosphatase, as described previously (17). Briefly, after visualization of the first primary mAb by AEC, a second mAb was applied, followed by incubation with alkaline phosphatase (AP)-conjugated rabbit anti-mouse IgG (DAKO) and then by mouse immunooalkaline phosphatase complexes (DAKO). Each incubation lasted for 30 min, separated by 5-min TBS washes. AP activity was detected by incubating the specimens for 30 min with both naphthol-AS-MX-phosphate and Fast Blue BB salt (Sigma), giving a blue color. For inhibition of endogenous AP activity, levamisole (Sigma) was added to the developing solution. The labeling combinations are listed in Table II. Factor VIII was used to confine addresses to endothelial cells as previously described (6).

Controls

Tonsil and skin specimens from chronic inflammatory lesions of psoriasis and lichen planus were used as positive controls. Skin specimens incubated without the primary mAb served as negative controls.

Quantification

Masked enumeration of cells was done at 400 × magnification with the use of an ocular grid consisting of a simple square lattice of 100 test points. The field of view comprised the stained cells in the epidermis per millimeter length of surface line, and in the dermis per square millimeter of dermis reaching 0.4 mm below the lowest rete ridges. The mean value of counted cell profiles of three sequential horizontal fields gave the relative density of the cells in the epidermis and the upper dermis, respectively. Evaluation of address expression on vascular endothelium was conducted by enumeration of positively stained endothelial cells, as previously described (6).

Statistical analysis

The Kruskal-Wallis ANOVA by ranks test was used to investigate differences in the number of cells in biopsies taken from center, edge and 2 cm distance. The Mann-Whitney U test was used to investigate the significance of differences in cell numbers between two of these three groups. In both analyses, the biopsy location was used as independent variable and a p-value < 0.05 was considered statistically significant. Correlations between cells and the addressins were investigated by Spearman rank order correlation test.

RESULTS

E-selectin, ICAM-1 and VCAM-1 expression on vascular endothelium

E-selectin stained the vascular endothelium in all the tested areas of the ulcer (Figs. 1a, 2). The number of endothelial

### Table I. Primary monoclonal antibodies used in the study

| Antibody | Epitope identified | Tissue reactivity | Company | Product no. | Dilution |
|----------|--------------------|------------------|---------|-------------|---------|
| NA/34    | CD1a               | Langerhans’ cells| Dako (Glostrup, Denmark) | M721 | 1:10 |
| UCHT1    | CD3                | Pan T cells      | Dako (Glostrup, Denmark) | M835 | 1:20 |
| EBM11    | CD68               | Macrophages-monocytes| Dako (Glostrup, Denmark) | M718 | 1:80 |
| RM3M     | CLA/HECA-452       | Leukocytes, HEVs | Dako (Glostrup, Denmark) | * | * |
| IOT-16   | LFA-1/CD11         | Leukocytes       | Immunotech (Marseilles, France) | 0157 | 1:70 |
| IOP49D   | VLA-4/CDw49d       | Leukocytes, fibronectin | Immunotech (Marseilles, France) | 0764 | 1:100 |
| BBIG-E6  | E-selectin         | Activated endothelium| Brit. Bio. Tech. (Abingdon, UK) | BBA1 | 1:600 |
| 84H10    | ICAM-1/CD54        | Endothelium, APC | Immunotech (Marseilles, France) | 0753 | 1:40 |
| BBIG-V1  | VCAM-1             | Activated endothelium| Brit. Bio. Tech. (Abingdon, UK) | BBA5 | 1:900 |
| F8/86    | Factor VII         | Endothelium      | Dako (Glostrup, Denmark) | M616 | 1:100 |

CD1a = Langerhans’ cells, CD3 = T lymphocytes, CD68 = macrophages, LFA-1 = lymphocyte function-associated antigen-1, CLA = cutaneous lymphocyte-associated antigen, VLA-4 = very late activation antigen-4, ICAM-1 = intercellular adhesion molecule-1, VCAM-1 = vascular cell adhesion molecule-1. *Gift of Dr. Robert Rothlein, Boehringer Ingelheim; HEV = high endothelial venules, APC = antigen-presenting cells.
cells (EC) expressing E-selectin was highest at the edge and lowest 2 cm distant from the ulcer \((p < 0.05)\) (Fig. 2). No difference in distribution of E-selectin-positive EC was observed between other regions of the ulcer. Double-staining with anti-factor-VIII confined ICAM-1 (Fig. 1b) and VCAM-1 to the EC. The number of ICAM-1+ EC increased towards the center of the ulcer \((p < 0.05)\) (Fig. 2). A significant difference was observed when comparing center versus edge \((p < 0.05)\) and center versus distant \((p < 0.01)\). VCAM-1 was weakly expressed on a minor portion of the blood vessels in less than 30% of the sections, with no difference in distribution between the regions of the ulcer (Fig. 2). The lumen area of blood vessels was packed with leukocytes to less than a third in all sections.

**CLA and LFA-1 expression on CD1a+ epidermal Langerhans’ cells**

The mean number of CLA+CD1a+ cells at the distant area was approximately three times higher than at the edge of the ulcer \((p < 0.01)\). Eighty percent of the CD1a+ cells expressed the CLA homing receptor at the edge of the ulcer as compared to 51% at the distant area (Table III, Fig. 1c). Langerhans’ cells double-stained for both CD1a and LFA-1 were found in only one biopsy taken 2 cm distant from the ulcer edge.

**CLA, LFA-1 and VLA-4 expression on CD3+ lymphocytes and on CD68+ macrophages**

A significant difference in distribution of the CLA+CD3+ cell population was observed between the three regions of the ulcer \((p < 0.01)\) and between edge and distant areas \((p < 0.01)\), but not between the center versus the other two areas (Figs. 1d, 1e, 3a). The highest proportion of lymphocytes expressing the CLA skin-homing receptor was found at the edge of the ulcer (62%), followed by 58% at the center and 50% at 2 cm lateral to the edge \((p < 0.05)\) (Table III). The majority of lymphocytes in the ulcer expressed LFA-1 (85–89%) (Table III; Fig. 1f). However, no significant difference was observed in the distribution of LFA-1+CD3+ cells between the different regions of the ulcer. Only 21–30% of the lymphocytes in the ulcer expressed VLA-4 (Table III). Neither the number of VLA-4+CD3+ cells nor the proportion of total CD3+ cell populations demonstrated significant differences.

---

*Fig. 1.* Expression of E-selectin (a), ICAM-1 (b), LFA-1 (f) and CLA (c-e) in the different regions of the chronic leg ulcer. Stainings: blue = immunoalkaline phosphatase; brown = three-step immunoperoxidase; brown on blue = expression of two receptors on the same cell. (a) E-selectin expression on vascular-endothelial cells. (b) ICAM-1 and Factor VIII expression on vascular-endothelial cells (tailed arrows point at Factor VIII = blue; non-tailed arrows point at ICAM-1 on the luminal surface = brown). (c) CLA and CD1a expression on Langerhans’ cells (CD1a = blue, CLA = brown). (d & e) CLA and CD3 expression on lymphocytes (CD3 = blue, CLA = brown). (f) LFA-1 and CD3 expression on lymphocytes (CD3 = blue, LFA-1 = brown). Biopsies (b, c, e and f) were obtained from region 2 cm distant to the margin of the ulcer, and (a) and (d) from the ulcer margin. The original magnification for (d) and (f) is ×200, for (c) ×400, and for (a), (b) and (e) ×1000. For abbreviations, see Table II.
The edge and distant areas of the ulcer differed in the mean numbers of LFA-1+CD68+, 27.1 and 15.4, respectively ($p<0.05$). No difference was observed between other regions. Furthermore, no significant difference in the distribution of the CLA+CD68+ and VLA-4+CD68+ subsets between the various regions of the ulcer was observed. The proportions of macrophages expressing the CLA and LFA-1 homing receptors were small, 7–9% and 8–11%, respectively, while VLA-4 was demonstrated on 39–71% of the macrophages (Fig. 3; Table III). None of the macrophage fractions displayed any significant difference in distribution between the regions of the ulcer.

DISCUSSION

Previously, we showed that at 2 cm distant from the edge of the venous leg ulcer the epidermis was heavily infiltrated by Langerhans’ cells, and the dermis by T lymphocytes and macrophages and to a lesser extent by neutrophils (15). This region is also characterized by a decreased capillary density compared to the ulcer margin (18). In the present study, we found that also E-selectin is up-regulated at the ulcer’s distant region compared to its expression level in normal skin (12, 19). This provides further support of the notion that this region is actively involved in recruitment of leukocytes to the ulcer. The increased expression of E-selectin at the ulcer edge supports Veraart et al. (10) and differs from Weyl et al. (12). The discrepancy may reflect differences between active ulcers (10) and dermatoliposclerotic skin (12). The ongoing expression of E-selectin in chronic leg ulcers is in contrast to in vivo rapid down-regulation (20). This may reflect its in vivo expression of the more stable E-selectin type I form (21), and the high levels of IL-1 alpha and TNF alpha in the chronic leg ulcer fluid (22–24).

The increased CLA+ Langerhans’ cells from 2% in normal epidermis (25) to 51% at the 2 cm distant region and to 80% at the ulcer margin correlated with the increased expression of vascular E-selectin. The lack of LFA-1 expression by Langerhans’ cells rules out their recruitment through the ICAM-1/LFA-1 pathway. It is therefore concluded that the E-selectin/CLA pathway participates in the recruitment of more than half of epidermal Langerhans’ cells to the venous leg ulcer. The remaining Langerhans’ cells may be recruited by other adhesion-molecule pathways, including the sialyl Lewis X/CLA pathway (26).

In view of the neutrophil’s limited presence within the chronic leg ulcer, <7% of the cellular infiltrate, and of its marginal role in wound healing (15, 27), we focused in the present study on dermal recruitment of T lymphocytes and macrophages. The increase in CLA+ T cells from 41% in normal skin (28) to 50% at the 2 cm distant region, and to 62% at the ulcer margin, correlated with the increased expression of vascular E-selectin. This suggests that the E-selectin/CLA pathway takes part in recruiting CLA+ T cells to the ulcer. However, the percentage of CLA+ T cells in the ulcer was lower than the 85% in a range of inflammatory and neoplastic skin diseases (29). The reasons for the relatively lower recruitment of the skin homing CLA+ T cells to venous leg ulcer are not clear. The ICAM-1/LFA-1 pathway apparently plays a larger part in recruiting T cells to the ulcer, since ICAM-1 was up-regulated at the ulcer’s center and edge compared to the distant region, and LFA-1 was expressed on

---

**Fig. 2.** Number (mean ± SEM) of endothelial cells expressing addressins in various regions of the ulcers ($n=19$). ICAM-1 = intercellular adhesion molecule-1; VCAM-1 = vascular cell adhesion molecule-1.

**Fig. 3.** Number (mean ± SEM) of T lymphocytes (a) and macrophages (Mø; b) expressing homing receptors in various regions of the ulcers ($n=19$). LFA-1 = lymphocyte function associated antigen-1; CLA = cutaneous lymphocyte associated lymphocyte; VLA-4 = very late activation antigen-4.
approximately 90% of the T cells. The expression of VLA-4 on 30% of the T cells is in contrast to a previous report of a “massive accumulation of VLA-4+ lymphocytes in venous leg ulcer” (12). However, in that study (12) the VLA-4+ infiltrate was not dissected by dual staining with CD3 and CD68. Therefore, the VLA-4+ cells (12) could also represent macrophages, which we found to be numerous at the venous leg ulcer (15), and up to 70% of the CD68+ cells expressed VLA-4. Taken together, the data suggest that E-selectin/CLA and ICAM-1/LFA-1 pathways participate in recruiting the vast majority of T cells to the venous leg ulcer.

The low expression of CLA and LFA-1 on macrophages at the different regions of the ulcer (7–11%) and the low expression of vascular VCAM-1 do not support a substantial role in macrophage recruitment to the ulcer for any of the three analyzed pathways. VLA-4 can adhere to both VCAM-1 and extracellular matrix (30). Therefore, the high percentage of VLA-4+ macrophages (39–71%) may suggest that the VLA-4 serves to anchor the macrophages to extracellular matrix proteins (31).

The initial drive behind venous leg ulcer propagation is the reduction in capillary density within at least 2 cm of the ulcer margins (18), resulting in local changes that lead to up-regulation of E-selectin and possibly of other addressins. This, along with the constitutively expressed ICAM-1, increase the recruitment of Langerhans’ cells, T lymphocytes and macrophages to the distant region (15). The total T-cell population did not increase at the ulcer’s margin and center, indicating that T-cell recruitment peaks during the initial phase (15). The following expansion phase is represented at the ulcer’s margin and center regions of the ulcer (7–11%), which is characterized by a decrease in vascular ICAM-1 expression and T-cell population size (14). In contrast, we found an increased vascular ICAM-1 at the ulcer center, with no reduction in either T-cell or macrophage populations (15). These findings are part of the processes that divert leg ulcers from a healing course into a chronic course.

In conclusion, Langerhans’ cells, T cells and macrophages are each recruited by more than one adhesion-molecule pathway to any venous leg ulcer region. The region 2 cm distant from the ulcer edge participates in the evolution of the venous leg ulcer by up-regulating E-selectin and recruiting leukocytes. The peaked expression of vascular ICAM-1 and the maintenance of high-density infiltrate of T cells and macrophages at the center of the ulcers characterize the chronic status of the leg ulcers.

ACKNOWLEDGEMENTS

This work was supported by the Mauritzen la Fontaine Family Fund, the Danish Cancer Society and the Aage Bang Foundation. Professors Klaus Bendtzen and Magnus Ågren are gratefully acknowledged for their critical review of the manuscript.

REFERENCES

1. Hunt TK. Basic principles of wound healing. J Trauma 1990; 30(12 Suppl): S122–128.
2. Barbul A. Immune aspects of wound repair. Clin Plast Surg 1990; 17: 433–442.
3. Berg EL, Goldstein LA, Jutila MA, Nakache M, Picker LJ, Streeter PR, Wu NW, et al. Homing receptors and vascular addressins: cell adhesion molecules that direct lymphocytes to tumour necrosis factor-α-stimulated endothelial cells. Immunol Rev 1989; 108: 5–18.
4. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245–253.
5. Groves RW, Ross EL, Barker JNWN, MacDonald DM. Vascular cell adhesion molecule-1: expression in normal and diseased skin and regulation in vivo by interferon gamma. J Am Acad Dermatol 1993; 29: 67–72.
6. Norton J, Sloane JP, Al-Saffar N, Haskard DO. Vessel-associated adhesion molecules in normal skin and acute graft-versus-host disease. J Clin Pathol 1991; 44: 586–591.
7. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for the skin-homing T cells. Nature 1991; 349: 796–799.
8. Etzioni A. Adhesion molecules – their role in health and disease. Pediatric Res 1996; 39: 191–198.
9. De Boer OJ, Horst E, Pals ST, Bos JD, Das PK. Functional evidence that the HECA-452 antigen is involved in the adhesion of human neutrophils and lymphocytes to tumor necrosis factor-alpha-stimulated endothelial cells. Immunology 1994; 81: 359–365.
10. Veraart JCJ, Verhaegh MEJM, Neumann HAM, Hulsmans...
Adhesion molecules in venous leg ulcers

RFHJ, Arends JW. Adhesion molecule expression in venous leg ulcers. VASA 1993; 22: 213–218.

11. Hahn J, Junger M, Fredrich B, Zuder D, Steins A, Hahn M, Klyscz T. Cutaneous inflammation limited to the region of the ulcer in chronic venous insufficiency. VASA 1997; 26: 277–81.

12. Weyl A, Vanscheidt W, Weiss JM, Peschen M, Schön E, Simon J. Expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectin and their ligands VLA-4 and LFA-1 in chronic venous leg ulcers. J Am Acad Dermatol 1996; 34: 418–423.

13. Peschen M, Lahaye T, Henning B, Weyl A, Simon JC, Vanscheidt W. Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency. Acta Derm Venereol 1999; 79: 27–32.

14. Wakita H, Takigawa M. E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-induced/memory T cells in psoriatic plaques. Arch Dermatol 1994; 130: 457–463.

15. Rosner K, Ross C, Karlmark T, Petersen AA, Gottrup F, Vejlsgaard GL. Immunohistochemical characterization of the cutaneous cellular infiltrate in different areas of chronic leg ulcer. APMIS 1995; 103: 293–299.

Boenisch T. Staining methods. In: Naish SJ, editor. Handbook of Immunohistochemical Staining Methods. California, USA: DAKO Corporation; 1989.

17. Cordell JL, Falini B, Erber W, Ghosh AK, Abdulfazl Z, Macdonald S, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219–9.

18. Gschwendtner ME, Ambrozy E, Fasching S, Willfort A, Schneider B, Böhler K, et al. Microcirculation in venous ulcers and the surrounding skin: findings with capillary microscopy and a laser Doppler imager. Eur J Clin Invest 1999; 29: 708–716.

19. Groves RW, Allen MH, Barker JN, Haskard DO, MacDonald DM. Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br J Dermatol 1991; 124: 117–123.

20. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243: 1160–1165.

21. Chu W, Presky DH, Swerlick RA, Burns DK. Alternatively processed human E-selectin transcripts linked to chronic expression of E-selectin in vivo. J Immunol 1994; 153: 4179–4189.

22. Trengove NJ, Bielfeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Rep Reg 2000; 8: 13–15.

23. Wallace HJ, Stacey MC. Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers – correlations to healing status. J Invest Dermatol 1998; 110: 292–296.

24. Sepp NT, Gille J, Li Lj, Caughman SW, Lawley TJ, Swerlick RA. A factor in human plasma permits persistent expression of E-selectin by human endothelial cells. J Invest Dermatol 1994; 102: 445–450.

25. Bos JD, de Boer OJ, Tibosch E, Das PK, Pals ST. Skin-homing T lymphocytes: detection of cutaneous lymphocyte associated antigen (CLA) by HECA-452 in normal human skin. Arch Dermatol Res 1993; 285: 179–183.

26. Ross EL, Barker JN, Allen MH, Chu AC, Groves RW, MacDonald DM. Langerhans’ cell expression of the selectin ligand, sialyl Lewis x. Immunology 1994; 81: 303–308.

27. Falanga V, Zitelli JA, Eaglstein WH. Wound healing. J Am Acad Derm 1988; 19: 559–563.

28. Picker LJ, Treer JR, Ferguson-Darnell-B, Collins PA, Bergstresser Terstappen LW. Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. J Immunol 1993; 150: 1122–1136.

29. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990; 136: 1053–1068.

30. Chan PY, Aruffo A. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem 1993; 268: 24655–24664.

31. Luscinakas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEB J 1994; 8: 929–938.